Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of nupr1 inhibitors in the preparation of bladder cancer treatment drugs

A technology of therapeutic drugs and inhibitors, applied in the field of NUPR1 inhibitors and preparation of bladder cancer therapeutic drugs, which can solve the problems of low tumor cell interference efficiency and discomfort of bladder cancer tumor cell interference, etc.

Active Publication Date: 2021-04-09
CHANGZHOU NO 2 PEOPLES HOSPITAL +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the interference efficiency of the interference sequence for tumor cells is not high, and it is not suitable for interference with bladder cancer tumor cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of nupr1 inhibitors in the preparation of bladder cancer treatment drugs
  • Use of nupr1 inhibitors in the preparation of bladder cancer treatment drugs
  • Use of nupr1 inhibitors in the preparation of bladder cancer treatment drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Expression of NUPR1 in Bladder Cancer Cells

[0028] According to the analysis of the TCGA database, the present invention shows that the expression of NUPR1 in the high-grade bladder cancer tissue is higher than that in the low-grade group, and the difference is statistically significant ( figure 1 A: The expression of NUPR1 in high-grade bladder cancer tissue is higher than that in low-grade cancer tissue, Pfigure 1 B: In stage group, NUPR1 expression level: stage IV is higher than stage III and stage II is higher, the difference is statistically significant (P=0.003)). The above analysis suggests that NUPR1 has clinical relevance, and the subsequent cellular functional mechanism needs to be further studied.

Embodiment 2

[0029] Example 2: Preparation of NUPR1 interference lentivirus

[0030] The second-generation self-inactivating lentiviral packaging system is used for virus packaging, including three plasmids:

[0031] (1) Tool vector plasmid carrying NUPR1 interference target (vector GV277: pFU-GW-009-hU6-MCS-EGFP-IRES-puromycin, such as figure 2 As shown, the insertion interferes with NUPR1 mRNA: 5'-AAGAAAGCTACAGAAAGAAACT-3' sequence);

[0032] (2) Virus packaging helper plasmid Helper1.0 (gag gene containing HIV virus, which encodes the main structural protein of the virus; pol gene, which encodes virus-specific enzymes; rev gene, which encodes a regulatory factor that regulates the expression of gag and pol genes);

[0033] (3) Helper2.0 (contains the VSV-G gene derived from herpes simplex virus and provides the envelope protein required for virus packaging).

[0034] The above three plasmids were co-transfected into 293T cells, the cell supernatant was collected, and the virus was ob...

Embodiment 3

[0035] Example 3: Inhibitory effect of NUPR1 interference lentivirus on muscle invasive bladder cancer tumor cells

[0036] (1) In order to evaluate the functional role of NUPR1 in bladder cancer, the present invention designs the following functional experiments for verification. First, the plate cloning experiment was carried out, and the experiment was divided into NUPR1 interference group, control group (control virus sequence: 5'-TTCTCCGAACGTGTCACGT-3') and normal 5637 group, and the number of clones was observed after 2 weeks of culture. The results are shown in Table 1. It can be seen from Table 1 that the number of clones in the NUPR1 interference group is the least, indicating that it can inhibit the ability of cell clone formation

[0037] Table 1 Clone cell data

[0038] test group Early stage of experiment Number of clones after 2 weeks Interference rate ShNUPR1 1000 cells 28±12 99％ ShCtrl 1000 cells 58±22 0 Normal 1000 cel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides a use of a NUPR1 inhibitor in the preparation of a drug for treating bladder cancer, which belongs to the field of biomedical research. By studying the expression level of NUPR1 in muscle-invasive bladder cancer, the present invention finds that it is closely related to the growth, proliferation, differentiation and metastasis of muscle-invasive bladder cancer tumor cells. The growth of muscle-invasive bladder cancer tumor cells can be significantly inhibited by silencing the expression of NUPR1 gene. The present invention obtains a specific shRNA sequence through sequence design and a large number of experimental verifications, and reduces the expression of NUPR1 by 95% to 99% after packaging with lentivirus.

Description

technical field [0001] The invention relates to the field of biomedical research, in particular to a NUPR1 inhibitor and its use in preparing bladder cancer treatment drugs. Background technique [0002] NUPR1 (Nuclear protein-1) molecule is mainly located in the nucleus and is a transcriptional regulator of an unstable secondary mechanism containing 82 amino acids. After cleavage two subunits are formed, type a and type b. In 1997, the NUPR1 gene was discovered during the initial study of pancreatitis damage in rats. Because of its relative molecular weight of 8872.7Da, it was also named p8. NUPR1 has transcriptional activity, and has been confirmed to play an important role in the occurrence, development and metastasis of various tumors. [0003] Studies have shown that NUPR1 is related to a variety of non-neoplastic disease processes, such as pancreatitis, diabetes and its complications, cardiomyopathy, and stress injury of the nervous system. In terms of tumors, NUPR1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7105A61K48/00A61P35/00
CPCA61K31/7105A61P35/00
Inventor 张力峰左立高林生糜远源陈加生
Owner CHANGZHOU NO 2 PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com